Last reviewed · How we verify
Recombinant Anti-EGFr Antibody
Recombinant Anti-EGFr Antibody is a Biologic drug developed by Sichuan Kelun Pharmaceutical Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | Recombinant Anti-EGFr Antibody |
|---|---|
| Sponsor | Sichuan Kelun Pharmaceutical Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
- A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (PHASE1)
- Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Anti-EGFr Antibody CI brief — competitive landscape report
- Recombinant Anti-EGFr Antibody updates RSS · CI watch RSS
- Sichuan Kelun Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about Recombinant Anti-EGFr Antibody
What is Recombinant Anti-EGFr Antibody?
Recombinant Anti-EGFr Antibody is a Biologic drug developed by Sichuan Kelun Pharmaceutical Co., Ltd.
Who makes Recombinant Anti-EGFr Antibody?
Recombinant Anti-EGFr Antibody is developed by Sichuan Kelun Pharmaceutical Co., Ltd (see full Sichuan Kelun Pharmaceutical Co., Ltd pipeline at /company/sichuan-kelun-pharmaceutical-co-ltd).
What development phase is Recombinant Anti-EGFr Antibody in?
Recombinant Anti-EGFr Antibody is in Phase 1.